$587 Million is the total value of BVF INC/IL's 30 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $60,015,000 | +65.2% | 2,278,459 | +33.8% | 10.23% | +39.3% |
| CTIC | Buy | CTI BIOPHARMA CORP | $53,869,000 | +269.0% | 43,795,613 | +338.0% | 9.18% | +211.3% |
| ONTY | Buy | ONCOTHYREON INC | $41,735,000 | -6.9% | 18,799,368 | +14.9% | 7.11% | -21.5% |
| CYTK | Buy | CYTOKINETICS INC | $30,550,000 | +116.7% | 2,920,628 | +38.6% | 5.21% | +82.8% |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $27,384,000 | +14.4% | 1,441,287 | +41.8% | 4.67% | -3.5% |
| ARQL | Buy | ARQULE INC | $14,777,000 | +20.3% | 6,809,843 | +3.7% | 2.52% | +1.5% |
| QLTI | Buy | QLT INC | $14,269,000 | +43.5% | 5,364,385 | +43.5% | 2.43% | +21.1% |
| CTMX | New | CYTOMX THERAPEUTICS INC | $12,707,000 | – | 608,848 | +100.0% | 2.17% | – |
| TBRA | Buy | TOBIRA THERAPEUTICS INC | $12,597,000 | +11.0% | 1,253,401 | +6.7% | 2.15% | -6.4% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $12,450,000 | – | 300,000 | +100.0% | 2.12% | – |
| NVLS | New | NIVALIS THERAPEUTICS INC | $9,249,000 | – | 1,195,013 | +100.0% | 1.58% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $9,050,000 | +5.8% | 1,125,572 | +8.7% | 1.54% | -10.8% |
| GTXI | Buy | GTX INC DEL | $7,814,000 | -4.6% | 11,163,136 | +3.6% | 1.33% | -19.5% |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $4,288,000 | +111.8% | 4,777,381 | +91.1% | 0.73% | +78.7% |
| PTIE | Buy | PAIN THERAPEUTICS INC | $3,242,000 | +90.7% | 1,852,353 | +99.4% | 0.55% | +61.2% |
| NRXGQ | New | NEPHROGENEX INC | $627,000 | – | 392,156 | +100.0% | 0.11% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.